Study summary
Camlipixant reduced coughing by about a third in a mid-stage trial
34.4%fewer coughs over 24 hours at 50 mg, compared with placebo
What was tested
Camlipixant, a P2X3-blocking pill that calms overactive cough nerves, against placebo in adults with chronic cough that did not respond to other treatment.
What they found
- At 50 mg, 24-hour cough frequency fell 34.4% more than with placebo.
- Two later phase 3 trials gave mixed results, and the maker stopped development in July 2026.
What it means
Shows the limits of this drug class: real but modest effects that have not been enough for approval in the US.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.